Similarly, use of everolimus in a patient with Peutz–Jeghers syndrome-induced advanced pancreatic cancer with presumed mTOR hyperactivation through loss of STK11/LKB1 leads to 9 months progression-free survival (44). The gene discussed is STK11; the disease is familial pancreatic carcinoma.